Paclitaxel Accord
Description: An antitumour cancer medicine belonging to a group of medicines called taxanes, which inhibit the growth of cancer cells by preventing cell division. It is a clear, colourless to slightly yellow, viscous solution that must be diluted before intravenous infusion.
Share Now
Additional Information
Product Name: Paclitaxel Accord 6 mg/ml concentrate
Active Ingredient: Paclitaxel
Description: An antitumour cancer medicine belonging to a group of medicines called taxanes, which inhibit the growth of cancer cells by preventing cell division. It is a clear, colourless to slightly yellow, viscous solution that must be diluted before intravenous infusion.
Indication: Indicated for the treatment of several types of cancer:
- Ovarian Cancer: As first-line therapy (combined with cisplatin) or as second-line therapy after standard platinum-based treatments have failed.
- Breast Cancer: As adjuvant treatment following standard therapy, as first-line treatment for advanced or metastatic disease (often in combination with an anthracycline or trastuzumab), or as a single agent for metastatic disease.
- Advanced Non-Small Cell Lung Cancer (NSCLC): In combination with cisplatin for patients not eligible for surgery or radiation therapy.
- AIDS-Related Kaposi’s Sarcoma: For patients who have failed prior liposomal anthracycline therapy.
Strength: 6 mg/ml. (Available in various vial sizes, such as 30 mg/5 ml, 100 mg/16.7 ml, 300 mg/50 ml, and 600 mg/100 ml).
Business Partner: Accord Healthcare
Related Products
Related products
Disclaimer
Pharma Solutions is the master distributor for the listed products in Egypt. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.